EXEL vs OABI
EXEL: Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline of next-generation small molecules and antibody-drug conjugates. OABI: OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical and biotech partners.
Side-by-side fundamentals
| Metric | EXEL | OABI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $54.98 | $2.11 | |
| Market cap as of 2026-07-23 | $14.0B | $300M | |
| P/E as of 2026-07-23 | 16.74 | n/a | |
| PEG as of 2026-07-23 | 1.09 | n/a | |
| Net margin as of 2026-07-23 | +35.1% | -187.6% | EXEL higher |
| Gross margin as of 2026-07-23 | +96.4% | +98.9% | OABI higher |
| Operating margin as of 2026-07-23 | +39.4% | -200.3% | EXEL higher |
| ROE as of 2026-07-23 | +40.2% | -20.3% | EXEL higher |
| ROA as of 2026-07-23 | +30.5% | -18.1% | EXEL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +7.9% | +8.2% | OABI higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | -31.9% | EXEL higher |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 0.41 | 0.44 | |
| 1-year return as of 2026-07-22 close | +26.8% | +5.6% | EXEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.